Essay On Cipla

PROJECT OF MORAL LEADER

SUBMITTED TO- SUBMITTED BY:-

PROF. K.N.CHAUBEY RASHMI JHA PGDM20150034 History: Cipla was founded by Khwaja Abdul Hamied in 1935. The first product of Cipla was launched in year 1937. In 1939 after the start of World War II, Mahatama Gandhi requested

Although AZT was patented, which limited Cipla’s export options, the company launched a generic version on the Indian market at one-sixth the prevailing price of $12 for the required daily dosage.

Cipla withdrew from the AIDS market until 1997, when research showed that a combination of AIDS drugs was effective in controlling the disease. By this time the MNC’s had introduced twelve different drugs that could be used in various combinations to form suitable cocktails. Cipla entered the Indian market again in 1998 but despite the company’s efforts, by late 2002, the entire Indian market for anti-retrovirals barely amounted to $3 million annually, largely because the cost of the pharmaceuticals was still out of reach of the average patient.

In 2005, the Indian government authorized the National Aids Control Organization to buy antiretrovirals for free distribution in India. Cipla’s share of the Indian antiretrovirals market had grown to $6 million annually. They were active in dealing with private HIV sales in India but not so good in

UN Response in combating HIV/AIDS Pandemic

In 2010 UNAIDS, agency founded in 1996 to coordinate the activities of ten U.N. organizations. They announced HIV epidemic had been halted, prevention methods and treatment were working. UNAIDS noted that financial investment in the AIDS response flattened in 2009 and called for overhaul of the global approach to treatment through program called Treatment 2.0. that helped in improving healthcare delivery, effect on drug development and pricing and involving more community workers in treating AIDS patients.

CIPLA & Indian Pharma in 2010

• Cipla by 2010 offered more than 50 different dosage forms for asthma, cancer, depression, HIV and other diseases.

• The company had more than 40 sales offices and over 25 manufacturing plants in India, 11 approved by USFDA.

• Earned pre-tax profits of 23% in 2010 and enjoyed average annual growth rate of 22% from 2000-10.

CIPLA’s future strategy

• Will focus more on allied work and build public relations.

• Focus on growing area of its businesslike exporting patent –expired pharmaceuticals.

• Tieing up with MNC’s to generate third-line drug for